1. Home
  2. OCS

as of 12-12-2025 3:06pm EST

$20.62
$0.26
-1.25%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Chart Type:
Time Range:
Founded: 2003 Country:
Switzerland
Switzerland
Employees: N/A City: N/A
Market Cap: 1.0B IPO Year: N/A
Target Price: $39.80 AVG Volume (30 days): 93.1K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.67 EPS Growth: N/A
52 Week Low/High: $14.00 - $23.08 Next Earning Date: 11-10-2025
Revenue: $991,999 Revenue Growth: -8.87%
Revenue Growth (this year): 35% Revenue Growth (next year): 874.12%

AI-Powered OCS Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 60.55%
60.55%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: